A novel therapeutic vaccine targeting the soluble TNF α receptor II to limit the progression of cardiovascular disease: AtheroVax™

We describe a peptide vaccine targeting sTNFR2 in limiting the progression of atherosclerosis. A therapeutic vaccine limiting the progression of atherosclerosis will greatly contribute to the reduction in morbidity and mortality from cardiovascular disease. It is likely the vaccine will be used in combination with the current standards of care and lifestyle modifications.PMID:37534280 | PMC:PMC10392828 | DOI:10.3389/fcvm.2023.1206541

Source: Atherosclerosis - August 3, 2023 Category: Cardiology Authors: Patrick L Iversen Nicholas Kipshidze Nodar Kipshidze George Dangas Eduardo Ramacciotti Zurab Kakabadze Jawed Fareed Source Type: research